#KITE PHARMACEUTICALS STOCK FULL#
#KITE PHARMACEUTICALS STOCK TRIAL#
#KITE PHARMACEUTICALS STOCK LICENSE#
#KITE PHARMACEUTICALS STOCK PLUS#

On June 20, 2014, Kite's shares began trading on the NASDAQ Global Select Market under the symbol 'KITE'.

#KITE PHARMACEUTICALS STOCK FULL#

Kite raised net proceeds of approximately $134.1 million in its IPO of 8,625,000 shares of its common stock, including the full exercise of the underwriters' option. Kite presented details on key features of its manufacturing process in a poster presentation during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, May 30-June 3, 2014.

#KITE PHARMACEUTICALS STOCK LICENSE#

Kite entered into an exclusive, worldwide license agreement with the National Institutes of Health (NIH) to certain intellectual property related to T Cell Receptor (TCR)-based product candidates that target the NY-ESO-1 antigen for multiple cancer indications. On June 30, 2014, there were 38.3 million shares of common stock issued and outstanding. Kite has no outstanding debt as of June 30, 2014.

On June 30, 2014, Kite had $203.4 million in cash and cash equivalents. This increase primarily related to stock-based compensation of $2.3 million, as well as additional headcount. General and administrative (G&A) expenses were $3.7 million for the quarter ended June 30, 2014, compared to $0.3 million for the same period in 2013. This increase primarily related to stock-based compensation of $4.8 million, as well as additional R&D headcount to further the development of Kite's pipeline of eACT™-based product candidates. Research and development (R&D) expenses for the quarter ended Jwere $7.4 million, compared to $1.1 million for the second quarter of 2013. This increase primarily related to stock-based compensation of $7.0 million, as well as additional headcount. Total operating expenses for the quarter ended Jwere $11.1 million as compared to $1.4 million for the quarter ended June 30, 2013.

#KITE PHARMACEUTICALS STOCK PLUS#

Non-cash charges of approximately $13.1 million are included in the net loss for the second quarter of 2014, which included $7.0 million related to stock-based compensation and a one-time $6.1 million non-cash interest expense primarily related to the conversion of $50.0 million of principal amount, plus accrued interest, in convertible notes to shares of Kite's common stock upon the closing of Kite's IPO at a discount to the IPO price. Basic and diluted net loss per share for the second quarter of 2014 was $2.27, compared to a net loss per share of $0.32 for the second quarter of 2013. Our near-term plan for this study is to commence enrollment of patients with a form of advanced, relapsed/refractory non-Hodgkin's lymphoma in the first half of 2015.'įor the second quarter ended June 30, 2014, Kite reported a net loss attributable to common stockholders of approximately $17.9 million, compared to a net loss attributable to common stockholders for the quarter ended Jof $1.7 million.

#KITE PHARMACEUTICALS STOCK TRIAL#

Belldegrun continued, 'Our product candidates are in multiple clinical trials being conducted by the National Cancer Institute (NCI), and based on the progress to date, Kite plans to file a corporate-sponsored Investigational New Drug application (IND) in the fourth quarter of this year to initiate the first multicenter trial of our lead product candidate, KTE-C19. Moreover, we broadened our collaboration with the National Institutes of Health through the execution of an additional exclusive license to cancer immunotherapy product candidates.'ĭr. In order to support our robust development plans, we also strengthened our research and development team with key strategic hires. 'Kite completed a highly successful IPO in June, which will help enable the advancement of our broad pipeline. 'Kite has achieved several significant milestones thus far in 2014, both in its corporate development and in its clinical development programs,' said Arie Belldegrun, M.D., Kite's President and Chief Executive Officer. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced financial results for the second quarter ended June 30, 2014. 14, 2014 (GLOBE NEWSWIRE) - Kite Pharma, Inc. Kite Advancing Clinical Development Pipeline of Its Proprietary eACT™-Based Product Candidates Successfully Completed Initial Public Offering, Raised Net Proceeds of $134.1 Million

Kite pharmaceuticals stock